Detailed curriculum vitae of HER2-targeted therapy
- PMID: 37075933
- DOI: 10.1016/j.pharmthera.2023.108417
Detailed curriculum vitae of HER2-targeted therapy
Abstract
With the booming development of precision medicine, molecular targeted therapy has been widely used in clinical oncology treatment due to a smaller number of side effects and its superior accuracy compared to that of traditional strategies. Among them, human epidermal growth factor receptor 2 (HER2)-targeted therapy has attracted considerable attention and has been used in the clinical treatment of breast and gastric cancer. Despite excellent clinical effects, HER2-targeted therapy remains in its infancy due to its resulting inherent and acquired resistance. Here, a comprehensive overview of HER2 in numerous cancers is presented, including its biological role, involved signaling pathways, and the status of HER2-targeted therapy.
Keywords: Cancer; HER2; Inhibitor; Resistance.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest The authors declare that there are no conflicts of interest.
Similar articles
-
Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway.Clin Breast Cancer. 2010 Nov;10 Suppl 3:S72-8. doi: 10.3816/CBC.2010.s.015. Clin Breast Cancer. 2010. PMID: 21115425 Review.
-
YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.Cancer Sci. 2020 Mar;111(3):849-856. doi: 10.1111/cas.14289. Epub 2020 Jan 16. Cancer Sci. 2020. PMID: 31856375 Free PMC article.
-
[Her2 a paradigm for targeted therapy].Bull Cancer. 2011 Oct;98(9):1011-7. doi: 10.1684/bdc.2011.1379. Bull Cancer. 2011. PMID: 21684838 Review. French.
-
Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.Curr Drug Targets. 2013 Jul;14(8):889-98. doi: 10.2174/13894501113149990161. Curr Drug Targets. 2013. PMID: 23531110 Review.
-
Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications.Crit Rev Oncog. 2012;17(1):1-16. doi: 10.1615/critrevoncog.v17.i1.20. Crit Rev Oncog. 2012. PMID: 22471661 Free PMC article. Review.
Cited by
-
UBR1 is a prognostic biomarker and therapeutic target associated with immune cell infiltration in gastric cancer.Aging (Albany NY). 2024 Aug 23;16(16):12029-12049. doi: 10.18632/aging.206079. Epub 2024 Aug 23. Aging (Albany NY). 2024. PMID: 39181686 Free PMC article.
-
The History and Development of HER2 Inhibitors.Pharmaceuticals (Basel). 2023 Oct 12;16(10):1450. doi: 10.3390/ph16101450. Pharmaceuticals (Basel). 2023. PMID: 37895921 Free PMC article. Review.
-
Anti-HER2 Immunoliposomes: Antitumor Efficacy Attributable to Targeted Delivery of Anthraquinone-Fused Enediyne.Adv Sci (Weinh). 2024 May;11(17):e2307865. doi: 10.1002/advs.202307865. Epub 2024 Feb 14. Adv Sci (Weinh). 2024. PMID: 38355309 Free PMC article.
-
Nano-engineering nanomedicines with customized functions for tumor treatment applications.J Nanobiotechnology. 2023 Aug 2;21(1):250. doi: 10.1186/s12951-023-01975-3. J Nanobiotechnology. 2023. PMID: 37533106 Free PMC article. Review.
-
Characterization of prevalent tyrosine kinase inhibitors and their challenges in glioblastoma treatment.Front Chem. 2024 Jan 8;11:1325214. doi: 10.3389/fchem.2023.1325214. eCollection 2023. Front Chem. 2024. PMID: 38264122 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous